Aura Biosciences offers high modeled upside and strong momentum ahead of binary clinical catalysts, but a quality score below the engine's floor, extreme insider selling, and sky-high implied volatility mark it as a highly speculative position.
Thesis pillars
- Quality Below Engine Floor→Stable
- Extreme Insider Selling Gate Failed↑Improving
- High Modeled Upside↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Aura Biosciences, Inc. (AURA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.66: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs) to treat solid tumors while preserving organ function. Its lead candidate, bel-sar, is in a global Phase 3 trial for early choroidal melanoma and in earlier-stage development... Read more
Sell if holding. Engine safety override at $7.66: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 59, MACD bullish. Score 5.6/10, moderate confidence.
Passes 5/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 1d<=7d. Suitability: speculative.
Recent developments
updated 2026-08-12Recent Developments — Aura Biosciences, Inc.
Latest news
- NEWS Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement Wit — benzinga Aug 11, 2026 neutral
- NEWS HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18 — benzinga Aug 11, 2026 neutral
- NEWS Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate — benzinga Aug 11, 2026 negative
- NEWS Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session — benzinga Jul 24, 2026 negative
- NEWS Why SAP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket — benzinga Jul 24, 2026 positive
Generated 2026-08-14T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebel-sar10-K Item 1A: 'We are heavily dependent on the success of bel-sar, our only product candidate to date.'
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMFounder Dr. Elisabet de los Pinos departed as CEO, President, and director effective April 30, 2026. The Board appointed Natalie Holles, former CEO of Third Harmonic Bio, as successor CEO, President, and Class I director effective the same date. No reason for departure cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.66: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 59, MACD bullish. Prior stop was $7.11. Score 5.6/10, moderate confidence.
Take-profit target: $15.31 (+100.2% upside). Prior stop was $7.11. Stop-loss: $7.11.
Concentration risk — Pipeline: bel-sar; Quality below floor (1.7 < 4.0).
Aura Biosciences, Inc. trades at a P/E of N/A (forward -4.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover AURA with a consensus score of 4.2/5. Average price target: $18.
What does Aura Biosciences, Inc. do?Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs) to treat solid...
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs) to treat solid tumors while preserving organ function. Its lead candidate, bel-sar, is in a global Phase 3 trial for early choroidal melanoma and in earlier-stage development for metastases to the choroid, ocular-surface cancers, and non-muscle invasive bladder cancer. The company has no approved products or product revenue and reported a $106.2 million net loss in 2025 with an accumulated deficit of $480.4 million.